Jump to main content
Jump to site search


Research and review articles in medicinal chemistry and related drug discovery science; the official journal of the European Federation for Medicinal Chemistry

Research Article

Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile

Corresponding authors
Pfizer Inc. Medicine Design, 610 Main Street, Cambridge, 02155 USA
E-mail: Kim.Huard@Pfizer.com
Pfizer Inc. Medicine Design, Eastern Point Road, Groton, 06340 USA
E-mail: Daniel.W.Kung@pfizer.com
Pfizer Inc. Drug Safety Research and Development, Eastern Point Road, Groton, 06340 USA
Pfizer Inc. Cardiovascular and Metabolic Disease Research Unit, 610 Main Street, Cambridge, 02155 USA
Med. Chem. Commun., 2017, Advance Article

DOI: 10.1039/C6MD00564K
Received 12 Oct 2016, Accepted 08 Nov 2016
First published online 22 Nov 2016

This article is part of themed collection: New Talent: Americas
Please wait while Download options loads
This article has not yet been cited.

Supplementary Info